<?xml version='1.0' encoding='utf-8'?>
<document id="24817647"><sentence text="Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics."><entity charOffset="82-94" id="DDI-PubMed.24817647.s1.e0" text="fruquintinib" /></sentence><sentence text="This study evaluated the preclinical pharmacokinetics (PK) and disposition of fruquintinib (HMPL-013), a small molecule vascular endothelial growth factor receptors inhibitor"><entity charOffset="78-90" id="DDI-PubMed.24817647.s2.e0" text="fruquintinib" /></sentence><sentence text="" /><sentence text="In vitro and in vivo PK/ADME assays were conducted" /><sentence text=" Allometry and PK modeling/simulation were conducted to predict human PK parameters and the time course profiles" /><sentence text="" /><sentence text="HMPL-013 has high permeability without efflux"><entity charOffset="0-8" id="DDI-PubMed.24817647.s7.e0" text="HMPL-013" /></sentence><sentence text=" It shows moderate oral bioavailability of 42-53 % and Tmax &lt; 4 h in mouse, rat, dog and monkey, with exposure-dose linearity proved in rats and dogs" /><sentence text=" No significant food effect is on dog PK" /><sentence text=" HMPL-013 has moderately high tissue distribution" /><sentence text=" It majorly distributes in gastrointestinal tract, liver, kidney, adrenal and adipose" /><sentence text=" The plasma protein binding fraction is 88-95 % in mouse, rat, dog and human, invariable up to 10 ÂµM" /><sentence text=" The in vivo clearance of HMPL-013 is low, consistent with the in vitro scaling" /><sentence text=" Three major oxidative metabolites were identified in liver microsomes of mouse, rat, dog, monkey and human" /><sentence text=" Dog is mostly similar to human regarding in vitro metabolism" /><sentence text=" Demethylation, hydroxylation and sequential glucuronidation are the major in vivo metabolic reactions" /><sentence text=" Direct urinary and biliary excretion of HMPL-013 is negligible" /><sentence text=" Metabolizing to M1 (demethylation), sequentially glucuronidating, followed by biliary excretion, and to a less extent, by urinary excretion, are important elimination pathways for HMPL-013 in rats" /><sentence text=" HMPL-013 has low risk of drug-drug interaction" /><sentence text=" It is predicted to have favorable human PK properties and low efficacious dose" /><sentence text="" /><sentence text="HMPL-013 demonstrates good preclinical PK and enables successful human PK and dose projection" /><sentence text=" It is valuable for further clinical development" /><sentence text="" /></document>